A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults ≥18 Yrs of Age
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2018
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A; AS03B
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
- 21 Oct 2011 Secondary endpoint 'Seroconversion-rate' has been met (3063141).
- 21 Oct 2011 Primary endpoint 'Geometric-mean-antibody-titre' has been met (3063141).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History